CRP and Increased total leukocyte count: Tocilizumab is a monoclonal antibody targeting interleukin-6, which plays a central role in inflammatory responses such as fever by inducing the production of CRP, differentiation of B cells into antibody-producing cells, differentiation of cytotoxic T cells, leukocytosis, and platelet proliferation, thereby causing acute-phase responses and other inflammatory reactions [11].